Felycin-CA1 (sirolimus delayed-release tablets) is indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).
Administer FELYCIN-CA1 at a target dosage of 0.3 mg/kg orally once weekly. FELYCIN-CA1 should be swallowed whole and not chewed. Do not split or crush tablets. FELYCIN-CA1 should be administered in conjunction with a meal. Always consult your veterinarian for the most accurate dosing, and to ensure proper use of this medication.
* Proven safe with a reasonable expectation of effectiveness; Felycin-CA1 is the first and only disease-modifying drug for cats with HCM.
* Felycin-CA1 is administered once-weekly and is formulated specifically for cats in small tablet sizes for easy administration.
* Felycin-CA1 is an affordable treatment option for cat owners that may prevent and delay progressive LV hypertrophy that affects 1 in 7 cats.
* Felycin-CA1 is a prescription drug to be prescribed by a licensed veterinarian after a confirmed HCM diagnosis. Felycin-CA1 should not be used in cats with diabetes mellitus. Do not administer in cats with pre-existing liver disease.
Reviews
There are no reviews yet.